Rabbit Polyclonal TFAM Antibody

+ +

•  

   
     Western blot analysis of lysates from Hela, HepG2, U-2OS cell line (from left to right),  using TFAM Antibody (C-term)(Cat.  #P32879).  P32879 was diluted at 1:1000 at each lane.  A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysates at 20ug per lane.    

•  

   
     Western blot analysis of lysate from 293T cell line, using TFAM Antibody (C-term) (Cat.  #P32879).  P32879 was diluted at 1:1000.  A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug.    

•  

   
     TFAM Antibody (C-term) (Cat. #P32879) western blot analysis in Hela,Jurkat,K562,MCF-7 cell line lysates (35ug/lane).This demonstrates the TFAM antibody detected the TFAM protein (arrow).    

•  

   
     Fluorescent confocal image of NCI-H460 cell stained with TFAM Antibody (C-term)(Cat#P32879). NCI-H460 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with TFAM primary antibody (1:25, 1 h at 37℃). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37℃).Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37℃). Nuclei were counterstained with DAPI (blue) (10 µg/ml, 10 min).TFAM immunoreactivity is localized to mitochondrion significantly.    

•  

   
     TFAM Antibody (C-term) (Cat. #P32879) flow cytometric analysis of K562 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.    

•  

   
     TFAM antibody (C-term) (Cat. #P32879) immunohistochemistry analysis in formalin fixed and paraffin embedded human testis carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.  This data demonstrates the use of the TFAM antibody (C-term) for immunohistochemistry.  Clinical relevance has not been evaluated.    

The TFAM (Mitochondrial Transcription Factor A) antibody is a crucial tool in studying mitochondrial biology and associated diseases. TFAM, encoded by the nuclear genome, is essential for mitochondrial DNA (mtDNA) maintenance, compaction, and transcription. It regulates mtDNA replication by organizing the mitochondrial nucleoid structure and facilitating interactions between replication/transcription machinery. Dysregulation of TFAM is linked to mitochondrial disorders, metabolic syndromes, neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), and cancer, making it a key research target.

The TFAM antibody enables detection and quantification of TFAM protein levels in techniques like Western blotting, immunofluorescence, and immunohistochemistry. It helps investigate TFAM’s role in mitochondrial dynamics, apoptosis, mitophagy, and cellular stress responses. Researchers use it to explore tissue-specific TFAM expression, mitochondrial biogenesis in metabolic tissues (e.g., muscle, liver), and its interplay with signaling pathways like PGC-1α. Commercial TFAM antibodies are typically raised against conserved epitopes, validated for specificity across human, mouse, and rat models.

This antibody is vital for advancing understanding of mitochondrial dysfunction mechanisms and potential therapeutic strategies for diseases involving mtDNA instability or energy metabolism defects.